m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0142)
| Name |
ICG-001
|
||||
|---|---|---|---|---|---|
| Synonyms |
ICG-001, 847591-62-2, 780757-88-2, ICG 001, (S,S)-ICG 001, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, ICG001, (6S,9aS)-6-(4-hydroxybenzyl)-N-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-hexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide, (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-(naphthalen-1-ylmethyl)-4,7-dioxo-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide, CHEMBL2312139, (6S,9AS)-N-BENZYL-6-(4-HYDROXYBENZYL)-8-(NAPHTHALEN-1-YLMETHYL)-4,7-DIOXOHEXAHYDRO-2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE, 780757-88-2 (ICG001), (5R,6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-[(naphthalen-1-yl)methyl]-4,7-dioxohexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide, (6S,9aS)-6-(4-Hydroxybenzyl)-8-[(naphthalen-1-yl)methyl]-4,7-dioxohexahydropyrazino[1,2-a]pyrimidine-1-carboxylic acid N-benzylamide, PRI 724, (6S,9AS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-8-(NAPHTHALEN-1-YLMETHYL)-4,7-DIOXO-TETRAHYDRO-2H-PYRAZINO[1,2-A]PYRIMIDINE-1-CARBOXAMIDE, MFCD12196918, MLS006011197, SCHEMBL178745, CHEBI:95032, (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-[(naphthalen-1-yl)methyl]-4,7-dioxo-octahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, EX-A1745, ICG-001, XIB59162, BDBM50468575, HB0331, NSC756641, s2662, s8262, AKOS015966600, BCP9000771, CCG-269997, CCG-269998, CS-0273, FI24532, NSC-756641, NCGC00263116-01, (6S,9AS)-HEXAHYDRO-6-[(4-HYDROXYPHENYL)METHYL]-8-(1-NAPHTHALENYLMETHYL)-4,7-DIOXO-N-(PHENYLMETHYL)-2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE, AC-32988, AS-16543, HY-14428, SMR004702966, BRD-K73261812-001-01-1, Q27166797, (6S,9aS)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrimido[1,2-a]pyrazine-1-carboxamide, (6S,9aS)-rel-hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine- 1(6H)-carboxamide
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C33H32N4O4
|
||||
| InChI |
InChI=1S/C33H32N4O4/c38-27-15-13-23(14-16-27)19-29-32(40)35(21-26-11-6-10-25-9-4-5-12-28(25)26)22-30-36(18-17-31(39)37(29)30)33(41)34-20-24-7-2-1-3-8-24/h1-16,29-30,38H,17-22H2,(H,34,41)/t29-,30+/m0/s1
|
||||
| InChIKey |
HQWTUOLCGKIECB-XZWHSSHBSA-N
|
||||
| PubChem CID | |||||
| DrugBank ID | |||||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
| In total 1 item(s) under this drug | ||
| Crosstalk ID: M6ACROT05642 | ||
| m6A Regulator | YTH domain-containing family protein 2 (YTHDF2) | |
| m6A Target | Circ_RERE | |
| Epigenetic Regulator | Circ_RERE | |
| Regulated Target | hsa-miR-195-5p | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Osteoarthritis | |